Speaker
Dr
Serge HAAN
(CEA)
Description
Full Title : Molecular Imaging in Tissue and Cells by Computer-assisted Innovative
Multimode Mass Spectrometry
This project aims to develop new and improved technologies for Molecular Imaging
Mass Spectrometry (MIMS), enabling innovative approaches in functional genomics,
proteomics and metabolomics, as well as for investigation of cells and tissues.
Three objectives are considered as part of this project:
- Innovate MS imaging instrumentation through the development and application of
novel desorption, ionisation and detection techniques
- Advanced diagnostic methods for identifying diseases by study of molecular images,
- Monitoring of therapeutic effects on expression patterns of damaged and abnormal
cells or tissues,
This project is based on recent significant improvements in desorption and
ionisation techniques such as SIMS (Secondary Ion Mass Spectrometry) and MALDI
(Matrix Assisted Laser Desorption Ionisation) associated with Time of Flight mass
spectrometers which offer an outstanding ability to analyze organic molecules as
large as peptides or proteins at femtomole sample amounts. These techniques are
extrapolated to produce actual molecular images of flat specimen by mass
spectrometry with a micrometric lateral resolution.
This project will provide innovative analytical capabilities for mapping a variety
of biological compounds directly at the tissue or cell level by superpositioning
information from different sources.
Thus MIMS is an extraordinary new tool which could lead to completely new analysis
concepts.
In order to make it routinely accessible to users, it requires appropriate
instrumentation, sample preparation methodology and computerization with high
performance massive data acquisition and processing. Application-driven developments
of MIMS will be validated as part of this project by close collaboration of
pathologists, biologists, analytical chemists and informaticians, to achieve the
project objectives and lead to rapid industrial and clinical exploitation owing to
the active contribution of the SME's and the industrial partners of the consortium.
Authors
Dr
Bernhard SPENGLER
(Justus Liebig University)
Dr
Olivier LAPREVOTE
(Centre National de la Recherche Scientifique)
Dr
Ron HERREN
(Dutch Foundation for Fundamental Research on Matter)
Dr
Serge HAAN
(CEA)
Co-authors
Dr
Jean DAVOUST
(GENETHON)
Dr
Markus STOECKLI
(NOVARTIS Pharma AG)
Dr
Ronald SCHUT
(Power Computing & Communication UvA BV)
